Stockscreener 앱 받기
3.89
9.12%
0.325
시간 외 거래:
3.90
0.010
+0.26%
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Pyxis Oncology files prospectus for 39.2M share sale by existing holders - scanx.trade
Pyxis Oncology (PYXS) awards director options at $3.12 - Stock Titan
Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
PYXS Q1 2026 Earnings: Modest EPS Beat Points to Cost Discipline for Clinical-Stage Oncology FirmDividend Earnings Report - vinanet.vn
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo - The Globe and Mail
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Releases Q2 2026 Financial Results - AlphaStreet
Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pyxis Oncology Q2 loss widens 38%, misses EPS estimate - scanx.trade
Form 8K Pyxis Oncology Inc For: 13 August By Investing.com - Investing.com Nigeria
PYXS: MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026 - TradingView
Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Pyxis Oncology Reports $25.3 Million Second-Quarter Net Loss - Quiver Quantitative
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - The Manila Times
Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS - Moomoo
Pyxis Oncology Q2 FY26 net loss widens to $25.3 million - Bitget
Pyxis Oncology (PYXS) Rises 7.4% to $3.04 as Biotech Buying Momentum BuildsQuality Factor - Vinanet
currently "more than watching" heheheh - Moomoo
Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Gains 2.68% as Clinical-Stage Biotech Finds Buying SupportDealer Delta - vinanet.vn
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pyxis Oncology Inc (PYXS) Stock News Today - TradingKey
Price to earnings forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Price to sales forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
PYXS Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com - Investing.com South Africa
Wells Fargo Initiates Pyxis Oncology at Overweight With $12 Price Target - marketscreener.com
Pyxis Oncology (PYXS) Slides 7.67% as Biotech Momentum Fades, Testing Key Support ZoneSuperTrend - vinanet.vn
PYXS|Pyxis Oncology Inc|Price:2.910|Chg%:+0.300 - TradingKey
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pyxis Oncology Inc (PYXS) Institutional Confidence - TradingKey
Pyxis Oncology Inc (PYXS) Income Statement - TradingKey
Pyxis Oncology Inc (PYXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.610|Chg%:-0.070 - TradingKey
Pyxis Oncology Inc (PYXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYXS stock trades steady as Pyxis Oncology highlights cash runway and clinical progress - Ad-hoc-news.de
PYXS Q1 2026 Earnings: Narrower Loss Per Share Surprises Market as Pipeline Progress ContinuesEarnings Acceleration Picks - vinanet.vn
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology Q1 2026 Earnings: Narrower Loss Per Share Drives Positive Stock MovementSlow Growth Warning - dars.gov.et
Craig D Gordon Net Worth (2026) - GuruFocus
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Pyxis Oncology Inc. - GuruFocus
Pyxis Oncology Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEPS Growth Report - dars.gov.et
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin - Seeking Alpha
Pyxis Oncology (PYXS) Declines 7.87% as Stock Tests Key Support Near $2.34Percent Above MA - dars.gov.et
0.86%
0.31%
자본화:
|
볼륨(24시간):